SCLC stage limited and very limited Disease with and without operation

Abstract

Introduction: Small cell lung cancer makes up about 15 percent of all lung cancers. Extensive stage small cell lung cancer (ES-SCLC) carries a poor prognosis, and the thoracic progression is common. It is usually an aggressive cancer that tends to grow and spread quickly. Because of this, surgery is useful for very few patients with small cell lung cancer. Most people with limited-stage small cell lung cancer are treated with chemotherapy in combination with radiation therapy. Method: From 2010 to 2018 9 patients with SCLC very limited Disease was studied. From those there were 5 male with 67 and 4 female with 68 average years. In 3 patients we found stage IA1, one patient with stage IA2, one with IB, two with IIA and 2 patients with stage IIB. From 27 patients from 2010 to 2018 with limited disease there were 12 female (59 average years), 15 male with (68 average years). From those we found 7 patients with stage IIIA, 18 with stage IIIB and two with stage IIIC. The median survival time of patients with SCLC limited disease without OP was 29 months. The median survival time of 6 studied patients with SCLC limited disease with neoadjuvant chemotherapy with carboplatin and etoposide with and without combined radiotherapy and Follow up staging was 103 months. Discussion: Neoadjuvant chemotherapy with and without radiotherapy can significantly expand the median survival time of patients with SCLC limited disease. Further studies are needed with larger patient collective.